Fulltext

Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial

Phillips, Kelly-Anne ; Aldridge, Julie ; Ribi, Karin ; Sun, Zhuoxin ; Thompson, Alastair ; Harvey, Vernon ; Thürlimann, Beat ; Cardoso, Fatima ; Pagani, Olivia ; Coates, Alan ; Goldhirsch, Aron ; Price, Karen ; Gelber, Richard ; Bernhard, Jürg

In: Breast Cancer Research and Treatment, 2011, vol. 126, no. 1, p. 221-226

Ajouter à la liste personnelle
    Titre
    • Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial
    Auteur
    • Phillips, Kelly-Anne. Peter MacCallum Cancer Centre, The University of Melbourne, Melbourne, VIC, Australia
    • Aldridge, Julie. IBCSG Statistical Center, Dana-Farber Cancer Institute, Boston, MA, USA
    • Ribi, Karin. IBCSG Coordinating Center, Bern, Switzerland
    • Sun, Zhuoxin. IBCSG Statistical Center, Dana-Farber Cancer Institute, Boston, MA, USA
    • Thompson, Alastair. Ninewells Hospital, University of Dundee, Dundee, Scotland, UK
    • Harvey, Vernon. Auckland City Hospital, Auckland, New Zealand
    • Thürlimann, Beat. Breast Center, Kantonsspital, St. Gallen, Switzerland
    • Cardoso, Fatima. Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium
    • Pagani, Olivia. Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland
    • Coates, Alan. International Breast Cancer Study Group, Bern, Switzerland
    • Goldhirsch, Aron. Department of Medicine, European Institute of Oncology, Milan, Italy
    • Price, Karen. IBCSG Statistical Center, Frontier Science and Technology Research Foundation, Dana-Farber Cancer Institute, 44 Binney Street, Mailstop CLSB 11007, Boston, MA, USA
    • Gelber, Richard. IBCSG Statistical Center, Frontier Science and Technology Research Foundation, Dana-Farber Cancer Institute, Boston, MA, USA
    • Bernhard, Jürg. IBCSG Coordinating Center, Effingerstrasse 40, 3008, Bern, Switzerland
    Type de document
    • Postprint
    Langue
    • Anglais
    Publié dans
    • Breast Cancer Research and Treatment, 2011, vol. 126, no. 1, p. 221-226. Springer US; http://www.springer-ny.com
    Autre version électronique
    Identifiant OAI-PMH
    • oai:doc.rero.ch:322421
    Summary
    Endocrine therapy for breast cancer may affect cognition. The purpose of this study was to examine whether cognitive function improves after cessation of adjuvant endocrine therapy. Change in cognitive function was assessed in 100 postmenopausal breast cancer patients in the BIG 1-98 trial, who were randomized to receive 5years of adjuvant tamoxifen or letrozole alone or in sequence. Cognitive function was evaluated by computerized tests during the fifth year of trial treatment (Y5) and 1year after treatment completion (Y6). Cognitive test scores were standardized according to age-specific norms and the change assessed using the Wilcoxon signed-rank test. There was significant improvement in the composite cognitive function score from Y5 to Y6 (median of change=0.22, effect size=0.53, P<0.0001). This improvement was consistent in women taking either tamoxifen or letrozole at Y5 (P=0.0006 and P=0.0002, respectively). For postmenopausal patients who received either adjuvant letrozole or tamoxifen alone or in sequence, cognitive function improved after cessation of treatment